Cantor Fitzgerald Estimates Belite Bio FY2025 Earnings

Belite Bio, Inc (NASDAQ:BLTE) – Research analysts at Cantor Fitzgerald reduced their FY2025 earnings per share (EPS) estimates for shares of Belite Bio in a report released on Thursday, May 15th. Cantor Fitzgerald analyst J. Kim now forecasts that the company will post earnings per share of ($1.48) for the year, down from their prior estimate of ($1.36). Cantor Fitzgerald currently has a “Overweight” rating on the stock. The consensus estimate for Belite Bio’s current full-year earnings is ($1.17) per share.

Several other equities analysts also recently issued reports on BLTE. Benchmark restated a “buy” rating and set a $80.00 price objective on shares of Belite Bio in a report on Wednesday, March 26th. HC Wainwright restated a “buy” rating and set a $100.00 price target on shares of Belite Bio in a research note on Thursday, May 15th.

Belite Bio Price Performance

Shares of NASDAQ:BLTE opened at $64.81 on Monday. The business’s 50-day moving average is $61.63 and its 200 day moving average is $63.01. Belite Bio has a 1 year low of $43.70 and a 1 year high of $86.53. The firm has a market capitalization of $2.06 billion, a P/E ratio of -58.39 and a beta of -1.48.

Belite Bio (NASDAQ:BLTE) last posted its quarterly earnings data on Monday, March 17th. The company reported ($0.32) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.02).

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of BLTE. GAMMA Investing LLC lifted its holdings in shares of Belite Bio by 9,391.6% during the first quarter. GAMMA Investing LLC now owns 122,441 shares of the company’s stock worth $8,108,000 after purchasing an additional 121,151 shares during the period. Alyeska Investment Group L.P. acquired a new stake in Belite Bio during the 1st quarter valued at approximately $5,538,000. JPMorgan Chase & Co. boosted its holdings in Belite Bio by 130.3% in the fourth quarter. JPMorgan Chase & Co. now owns 14,636 shares of the company’s stock valued at $924,000 after purchasing an additional 8,280 shares during the last quarter. Bank of America Corp DE grew its position in Belite Bio by 36.4% during the 4th quarter. Bank of America Corp DE now owns 18,342 shares of the company’s stock worth $1,157,000 after purchasing an additional 4,891 shares during the period. Finally, BNP Paribas Financial Markets purchased a new position in shares of Belite Bio during the 4th quarter valued at about $155,000. 0.53% of the stock is owned by institutional investors and hedge funds.

Belite Bio Company Profile

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company’s lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients.